Oxidative stress and cardiovascular disease

Oxidative Stress, Disease and Cancer

Volumn , Issue , 2006, Pages 519-536

  Johar, Sofian ^a   MacCarthy, Philip A ^a   Shah, Ajay M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967372676     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860948046_0016     Document Type: Chapter

References (79)

1. Das DK, Maulik N, Engelman RM. Redox regulation of angiotensin II signaling in the heart. J. Cell. Mol. Med. 8: 144-152 (2004).
2. Li N, Karin M. Is NF-kappaB the sensor of oxidative stress? FASEB J. 13: 1137-1143 (1999).
3. Karin M, Shaulian E. AP-1: linking hydrogen peroxide and oxidative stress to the control of cell proliferation and death. IUBMB Life 52: 17-24 (2001).
4. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 24(4): 677-683 (2003).
5. Brown JM, Terada LS, Grosso MA, Whitmann GJ, Velasco SE, Patt A, Harken AH, Repine JE. Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused rat hearts. J. Clin. Invest. 81: 1297-1301 (1988).
6. Terada LS, Rubinstein JD, Lesnefsky EJ, Horwitz LD, Leff JA, Repine JE. Existence and participation of xanthine oxidase in reperfusion injury of ischemic rabbit myocardium. Am. J. Physiol. 260: H805-H810 (1991).
7. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJS, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105: 2619-2624 (2002).
8. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 111: 1201-1209 (2003).
9. Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, Jefferson A, Goh N, Rockett KA, Channon KM. Tetrahydrobiopterin-dependent preservation of nitric oxidemediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J. Clin. Invest. 112: 725-735 (2003).
10. Sbarra AJ, Karnovsky ML. The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J. Biol. Chem. 234: 1355-1362 (1959).
11. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc. Natl. Acad. Sci. USA 94: 14483-14488 (1997).
12. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86: 494-501 (2000).
13. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4: 181-189 (2004).
14. Babior BM. NADPH oxidase: an update. Blood 93: 1464 (1999).
15. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and fedox-sensitive signaling pathways. Circ. Res. 88: 888-894 (2001).
16. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285: R277-R297 (2003).
17. Griendling KK. Novel NAD(P)Hoxidases in the cardiovascular system. Heart 90: 491-493 (2004).
18. Park JB, Schiffrin EL. Small artery remodeling is themost prevalent (earliest?) form of target organ damage in mild essential hypertension. J. Hypertens. 19: 921-930 (2001).
19. Luscher TF, Barton M. Biology of the endothelium. Clin. Cardiol. 20: II-3-II-10 (1997).
20. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthineoxidase and extracellular superoxide dismutase. Circulation 106: 3073-3078 (2002).
21. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, Girelli A, Rodella L, Bianchi R, Sleiman I, Rosei EA. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with noninsulin- dependent diabetes mellitus. Circulation 103: 1238-1244 (2001).
22. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular physiology. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287: R1014-R1030 (2004).
23. Shokoji T, Nishiyama A, Fujisawa Y, Hitomi H, Kiyomoto H, Takahashi N, Kimura S, Kohno M, Abe Y. Renal sympathetic nerve responses to tempol in spontaneously hypertensive rats. Hypertension 41: 266-273 (2003).
24. Park JB, Touyz RM, Chen X, Schiffrin EL. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am. J. Hypertens. 15: 78-84 (2002).
25. Paravicini TM, Chrissobolis S, Drummond GR, Sobey CG. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke 35: 584-589 (2004).
26. Zalba G, Jose GS, Beaumont FJ, Fortuno MA, Fortuno A, Diez J. Polymorphisms and promoter overactivity of the p22phox gene in vascular smooth muscle cells from spontaneously hypertensive rats. Circ. Res. 88: 217-222 (2001).
27. Schachinger V, Britten MB, Dimmeler S, Zeiher AM. NADH/NADPH oxidase p22 phox gene polymorphismis associated with improved coronary endothelial vasodilator function. Eur. Heart J. 22: 96-101 (2001).
28. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44: 248-252 (2004).
29. Ormezzano O, Cracowski JL, Baguet JP, Francois P, Bessard J, Bessard G, Mallion JM. Oxidative stress and baroreflex sensitivity in healthy subjects and patients with mild-to-moderate hypertension. J. Hum. Hypertens. 18: 517-521 (2004).
30. Sagar S, Kallo IJ, Kaul N, Ganguly NK, Sharma BK. Oxygen free radicals in essential hypertension. Mol. Cell. Biochem. 111: 103-108 (1992).
31. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 22: 1845-1851 (2002).
32. Berry C, Anderson N, Kirk AJ, Dominiczak AF, McMurray JJ. Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart 86: 217-220 (2001).
33. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91: 2546-2551 (1993).
34. Mugge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ. Res. 69: 1293-1300 (1991).
35. Boger RH, Bode-Boger SM, Mugge A, Kienke S, Brandes R, Dwenger A, Frolich JC. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117: 273-284 (1995).
36. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T. Increased NADH-oxidase mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin- angiotensin system. Circulation 99: 2027-2033 (1999).
37. Miller FJ, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ. Res. 82: 1298-1305 (1998).
38. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis inApoEdeficient mice. Nat. Med. 4: 1189-1192 (1998).
39. Tangirala RK, Pratico D, FitzGerald GA, Chun S, Tsukamoto K, Maugeais C, Usher DC, Pure E, Rader DJ. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J. Biol. Chem. 276: 261-266 (2001).
40. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105: 1049-1056 (2000).
41. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103: 1597-1604 (1999).
42. Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, Finkel T. Vascular effects following homozygous disruption of p47phox: an essential component of NADPH oxidase. Circulation 101: 1234-1236 (2000).
43. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 20: 1529-1535 (2000).
44. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(−/−) mice. J. Clin. Invest. 108: 1513-1522 (2001).
45. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in ApoE-deficient mice. Circulation 103: 448-454 (2001).
46. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94: 2493-2503 (1994).
47. Faia KL, Davis WP, Marone AJ, Foxall TL. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in hamster aortic atherosclerosis: correlation with in situ zymography. Atherosclerosis 160: 325-337 (2002).
48. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98: 2822-2828 (1998).
49. Yamaguchi Y, Kunitomo M, Haginaka J. Assay methods of modified lipoproteins in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 781: 313-330 (2002).
50. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J. Cardiovasc. Pharmacol. 40: 611-617 (2002).
51. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 332: 1198-1203 (1995).
52. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-{alpha} and angiotensin II. Circulation 98: 794-799 (1998).
53. Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H, Hasegawa H, Akazawa H, Mizukami M, Nagai R, Komuro I. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem. Biophys. Res. Commun. 289: 901-907 (2001).
54. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J. Am. Coll. Cardiol. 28: 506-514 (1996).
55. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296 (2002).
56. MacCarthy PA, Grieve DJ, Li JM, Dunster C, Kelly FJ, Shah AM. Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104: 2967-2974 (2001).
57. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosteroneinfused rats. Biochem. Biophys. Res. Commun. 313: 812-817 (2004).
58. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ. Res. 93: 802-805 (2003).
59. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 280: C53-C60 (2001).
60. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll. Cardiol. 41: 2164-2171 (2003).
61. Palace V, Kumar D, Hill MF, Khaper N, Singal PK. Regional differences in non-enzymatic antioxidants in the heart under control and oxidative stress conditions. J. Mol. Cell. Cardiol. 31: 193-202 (1999).
62. Prasad K, Lee P, Mantha SV, Kalra J, Prasad M, Gupta JB. Detection of ischemia-reperfusion cardiac injury by cardiac muscle chemiluminescence. Mol. Cell. Biochem. 115: 49-58 (1992).
63. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. Caninemyocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ. Res. 54: 277-285 (1984).
64. Temsah RM, Netticadan T, Chapman D, Takeda S, Mochizuki S, Dhalla NS. Alterations in sarcoplasmic reticulum function and gene expression in ischemic-reperfused rat heart. Am. J. Physiol. 277: H584-H594 (1999).
65. Chen EP, Bittner HB, Davis RD, Van Trigt P, Folz RJ. Physiologic effects of extracellular superoxide dismutase transgene overexpression on myocardial function after ischemia and reperfusion injury. J. Thorac. Cardiovasc. Surg. 115: 450-458 (1998).
66. Yoshida T, Maulik N, Engelman RM, Ho YS, Das DK. Targeted disruption of the mouse Sod I gene makes the hearts vulnerable to ischemic reperfusion injury. Circ. Res. 86: 264-269 (2000).
67. Sethi R, Takeda N, Nagano M, Dhalla NS. Beneficial effects of vitamin E treatment in acute myocardial infarction. J. Cardiovasc. Pharmacol. Ther. 5: 51-58 (2000).
68. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A. Treatment with dimethylthioureaprevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ. Res. 87: 392-398 (2000).
69. Sia YT, Lapointe N, Parker TG, Tsoporis JN, Deschepper CF, Calderone A, Pourdjabbar A, Jasmin JF, Sarrazin JF, Liu P, Adam A, Butany J, Rouleau JL. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation 105: 2549-2555 (2002).
70. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90: 520-530 (2002).
71. Cox MJ, Hawkins UA, Hoit BD, Tyagi SC. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation 109: 2123-2128 (2004).
72. Rimm EB, Stampfer MJ. Antioxidants for vascular disease. Med. Clin. North Am. 84: 239-249 (2000).
73. Crawford RS, Kirk EA, Rosenfeld ME, LeBoeuf RC, Chait A. Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18: 1506-1513 (1998).
74. Davidge ST, Ojimba J, McLaughlin MK. Vascular function in the vitamin E deprived rat: an interaction between nitric oxide and superoxide anions. Hypertension 31: 830-835 (1998).
75. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don’t throw out the baby with the bath water. Circulation 107: 926-928 (2003).
76. Heitzer T, Herttuala SY, Wild E, Luoma J, Drexler H. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J. Am. Coll. Cardiol. 33: 499-505 (1999).
77. Gokce N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, Vita JA. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 99: 3234-3240 (1999).
78. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781-786 (1996).
79. Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, Tuomainen TP, Valkonen VP, Ristonmaa U, Lakka HM, Vanharanta M, Salonen JT, Poulsen HE. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 107: 947-953 (2003).